Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinica ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC-4881 in familial adenomatous polyposis. The company records milestone progress across its collaborations ...

Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...

Recursion Pharmaceuticals Inc (RXRX) showcases strong financial management and strategic partnerships while navigating challenges in drug discovery.

Apheris's ADMET Network will combine proprietary datasets in a privacy-preserving environment to accelerate AI drug discovery models.

T-cell engager (TCE) specialist Candid Therapeutics has entered into a reverse merger agreement with Rallybio that will allow ...

As the program engages more directly with global concerns such as the climate crisis, he will lead the way.

Totaligent (OTCID: TGNT) announced the execution of a binding Letter of Intent (LOI) with GloMed Solutions Limited Liability Company, a Japanese medical aesthetics and biologics distributor, to form a ...

Here's Why. Ethereum remains a focal point for institutional on-chain activity even as price momentum stalls. In 2026, Ether has retreated about 36% for the year, slipping back from the $3,000 milesto ...

While you can instantly Google how to fix anything today, you've likely never experienced the profound satisfaction of ...